Vaxil Bio (TSE:VXL) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Vaxil Bio Ltd., an Israeli biotech firm, has announced the termination of their proposed reverse takeover with Copper Bullet Mines Inc., and is now exploring other strategic options to enhance shareholder value. The company is also advancing its cancer therapy research, recently highlighting published results of a preclinical study in collaboration with Ben-Gurion University, indicating potential in treating aggressive liver metastasis of colorectal cancer. Vaxil continues to focus on its immunotherapy platform, including the development of its lead product, ImMucin™, alongside other promising vaccines and treatments.
For further insights into TSE:VXL stock, check out TipRanks’ Stock Analysis page.